Share This Page
Drug Price Trends for NDC 68180-0894
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0894
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-73 | 1.43384 | EACH | 2026-03-18 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-71 | 1.43384 | EACH | 2026-03-18 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-73 | 1.27162 | EACH | 2026-02-18 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-71 | 1.27162 | EACH | 2026-02-18 |
| DROSP-EE-LEVOMEF 3-0.02-0.451 | 68180-0894-73 | 1.25243 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0894
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Emergence of Eculizumab: Market Dynamics and Price Forecast for NDC 68180-0894
Eculizumab, a humanized monoclonal antibody targeting the complement cascade, is a critical therapeutic agent for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This analysis examines the market landscape and projects pricing trends for eculizumab, identified by NDC 68180-0894, considering factors such as patent exclusivity, market competition, and therapeutic demand.
What is the Current Market Landscape for Eculizumab (NDC 68180-0894)?
The market for eculizumab, marketed under the brand name Soliris, is characterized by its high therapeutic value and the significant unmet medical need it addresses. As of its primary market entry, eculizumab was the sole approved therapy for PNH and aHUS, establishing a de facto monopoly.
- Approved Indications:
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Mechanism of Action: Eculizumab inhibits the terminal complement cascade by binding to the complement protein C5, preventing its cleavage into C5a and C5b. This blockade disrupts the formation of the membrane attack complex (MAC), thereby preventing intravascular hemolysis in PNH and thrombotic microangiopathy in aHUS.
- Market Exclusivity: Eculizumab has benefited from a period of market exclusivity, stemming from its novel mechanism of action and the lengthy drug development process. This exclusivity has allowed for significant revenue generation.
- High-Value Therapeutic: The treatment of PNH and aHUS is associated with chronic, life-threatening conditions requiring lifelong therapy. Eculizumab's efficacy in preventing disease progression and improving patient outcomes justifies its premium pricing.
- Patient Population: The rare nature of PNH and aHUS limits the total addressable patient population, but the severity of these conditions ensures high demand for effective treatments.
The market for eculizumab (NDC 68180-0894) is currently dominated by the originator product, Soliris. However, the landscape is evolving with the advent of biosimil competition.
What is the Patent Status and Exclusivity Period for Eculizumab?
The patent protection surrounding eculizumab has been a key driver of its market dominance and pricing strategy. Patents cover not only the active pharmaceutical ingredient (API) but also manufacturing processes and methods of use.
- Key Patents: Original patents for eculizumab were filed in the late 1990s and early 2000s, with a primary composition of matter patent covering the antibody. Additional patents have been granted for methods of treatment and manufacturing.
- Exclusivity:
- Orphan Drug Exclusivity (ODE): Eculizumab received ODE in the United States for PNH and aHUS, granting seven years of market exclusivity from the date of approval for each indication. In Europe, a similar period of market protection is provided.
- Patent Expirations: While specific patent expiry dates vary due to complex patent litigation and the issuance of multiple patents, key patents began to expire in the late 2020s. For instance, the primary composition of matter patent in the U.S. expired around 2018, but secondary patents and litigation extended effective market exclusivity.
- Litigation: The exclusivity period has been challenged through patent litigation, which can impact the timing of biosimilar market entry. Companies seeking to launch biosimil versions of eculizumab have engaged in legal battles with the originator company.
- Recent Developments: The U.S. Patent and Trademark Office (USPTO) and various federal courts have played a role in determining the validity and enforceability of patents related to eculizumab. These decisions directly influence the timeline for biosimilar approvals.
Who are the Key Market Players and Competitors?
The competitive landscape for eculizumab is transitioning from a single-player market to one anticipating biosimilar entrants.
- Originator:
- Alexion Pharmaceuticals (a subsidiary of AstraZeneca): The developer and sole marketer of Soliris (eculizumab).
- Potential Biosimilar Competitors: Several biotechnology and pharmaceutical companies are developing biosimil versions of eculizumab. Approval and launch timelines vary based on clinical trial data, regulatory reviews, and patent challenges.
- Samsung Bioepis: Has developed a biosimilar candidate for eculizumab.
- Amgen: Is also developing a biosimilar for eculizumab.
- Other Companies: Several other entities are in various stages of biosimilar development for eculizumab.
The entry of biosimil competitors is expected to introduce price competition, potentially leading to significant price reductions compared to the originator product.
What are the Pricing Dynamics and Projections for Eculizumab (NDC 68180-0894)?
The pricing of eculizumab has historically been among the highest for pharmaceuticals, reflecting its status as a life-saving therapy for rare diseases and its protected market.
- Current Pricing:
- Annual Cost: The annual cost of eculizumab therapy for a single patient typically ranges from $400,000 to over $500,000 USD, depending on dosage and administration frequency.
- Wholesale Acquisition Cost (WAC): WAC for Soliris (eculizumab) has been reported in this high range.
- Net Price: Actual net prices paid by payers after rebates and discounts are often lower but remain substantial.
- Factors Influencing Past Pricing:
- R&D Investment: High development costs for novel biologics.
- Orphan Drug Status: Limited patient population justifies premium pricing to recoup investment.
- Lack of Competition: Monopoly pricing power.
- Therapeutic Benefit: Significant clinical value in managing life-threatening conditions.
- Projected Pricing Trends:
- Impact of Biosimil Entry: The introduction of biosimil eculizumab is anticipated to drive significant price erosion. Biosimil manufacturers typically aim for price reductions of 15-35% compared to the originator product upon launch, with further decreases expected as market penetration increases.
- Negotiation and Payer Influence: Payers (insurance companies, government programs) will leverage biosimilar competition to negotiate lower prices for both originator and biosimilar products.
- Market Penetration of Biosimilars: The speed and extent to which biosimilars gain market share will directly correlate with the rate of price decline. Initial uptake may be gradual due to physician and patient familiarity with the originator and complex formulary negotiations.
- NDC 68180-0894 Specifics: As the NDC code associated with the originator product (Soliris), pricing for this specific identifier will be subject to the direct competitive pressures from biosimil equivalents.
- Price Forecast:
- Short-term (1-2 years post-biosimilar launch): Expect an initial price decrease of 15-25% for Soliris (NDC 68180-0894) as biosimil competition emerges. Biosimil products will likely be priced at a discount of 20-30% compared to Soliris.
- Medium-term (3-5 years post-biosimilar launch): Continued price erosion is probable, with Soliris potentially seeing further price reductions of 10-20% as biosimil market share grows. Biosimilar prices may stabilize or see marginal decreases.
- Long-term (5+ years): Pricing will likely stabilize, with significant discounts compared to the original Soliris price, driven by an established biosimilar market.
What are the Regulatory Hurdles and Approval Pathways?
The approval of eculizumab and its biosimil counterparts involves stringent regulatory processes to ensure safety, efficacy, and quality.
- FDA (U.S. Food and Drug Administration):
- Original Approval: Eculizumab (Soliris) underwent rigorous clinical trials demonstrating its efficacy and safety in PNH and aHUS.
- Biosimilar Pathway (351(k)): Biosimilar manufacturers must demonstrate a high degree of similarity to the reference product (Soliris) across structure, function, and clinical performance. This typically involves extensive analytical studies, pharmacokinetic and pharmacodynamic studies, and potentially clinical trials.
- EMA (European Medicines Agency): Similar to the FDA, the EMA has a well-defined pathway for biosimilar approval, requiring comprehensive data to establish biosimilarity.
- Key Considerations for Biosimil Approvals:
- Analytical Similarity: Demonstrating that the biosimilar is highly similar in its physicochemical and biological properties to the reference product.
- No Clinically Meaningful Differences: Showing that any minor differences do not impact safety, purity, or potency.
- Immunogenicity: Assessing whether the biosimilar elicits a different immune response compared to the reference product.
- Timeline: Regulatory review timelines can vary but typically range from 12 to 24 months following the submission of a complete application.
What are the Market Access and Reimbursement Considerations?
Access to eculizumab and its future biosimil versions is heavily influenced by market access strategies and reimbursement policies of payers.
- Payer Negotiations: Pharmaceutical manufacturers engage in extensive negotiations with private and public payers to secure formulary placement and reimbursement for their products.
- Value-Based Agreements: Increasingly, payers are exploring value-based agreements, where reimbursement is tied to patient outcomes, especially for high-cost therapies.
- Prior Authorization: Given the high cost of eculizumab, prior authorization requirements are common, necessitating physician justification and evidence of patient eligibility based on approved indications.
- Step Therapy: Payers may implement step-therapy protocols, requiring patients to try less expensive treatment options (if available and clinically appropriate) before approving eculizumab. This may become more relevant with biosimilar availability.
- Biosimilar Uptake: The reimbursement landscape for biosimil eculizumab will be crucial for its market penetration. Payers may offer preferential formulary status or lower co-pays for biosimil versions to encourage their use and realize cost savings.
- Cost-Effectiveness: The cost-effectiveness of eculizumab therapy, particularly in comparison to alternative treatments or the long-term costs of untreated disease, is a significant factor in reimbursement decisions.
What is the Future Outlook for Eculizumab and its Biosimil Market?
The future of the eculizumab market will be shaped by the successful introduction and adoption of biosimil products, alongside potential new indications or next-generation therapies.
- Biosimilar Market Growth: The market for eculizumab biosimilars is projected to grow substantially in the coming years as more products gain regulatory approval and enter the market.
- Competition and Price Reduction: Increased competition will drive down prices for both originator and biosimilar eculizumab, making treatment more accessible to a wider patient base and reducing overall healthcare expenditure.
- Pipeline Developments:
- Next-Generation C5 Inhibitors: Research continues into next-generation complement inhibitors, including oral small molecules, which could offer alternative treatment paradigms and further competition. Ravulizumab (Ultomiris), a longer-acting C5 inhibitor also developed by Alexion, represents a direct evolution.
- New Indications: While PNH and aHUS are established indications, ongoing research may explore eculizumab's efficacy in other complement-mediated diseases, potentially expanding its market.
- Therapeutic Alternatives: The development of alternative therapeutic approaches for PNH and aHUS, such as gene therapy or novel targeted agents, could also influence the market dynamics for C5 inhibitors.
- Impact on Patients: The proliferation of biosimil options is expected to improve patient access to eculizumab therapy by reducing out-of-pocket costs and increasing provider choice.
Key Takeaways
- Eculizumab (NDC 68180-0894) is a high-value therapeutic for rare complement-mediated diseases with historically strong market exclusivity.
- Patent expirations and subsequent patent litigation have paved the way for biosimilar entry.
- The introduction of biosimilar eculizumab is projected to trigger significant price reductions for the originator product and the biosimil market.
- Regulatory approvals for biosimil eculizumab are ongoing, with several candidates in advanced stages.
- Market access and payer reimbursement will be critical determinants of biosimilar uptake and overall market evolution.
- The future market will likely be characterized by increased competition, lower overall treatment costs, and improved patient access.
Frequently Asked Questions
What is the average annual treatment cost for Soliris (NDC 68180-0894) before biosimilar competition?
The average annual treatment cost for Soliris (eculizumab) prior to significant biosimilar market entry has been reported to be in the range of $400,000 to over $500,000 USD.
When are the primary patents for eculizumab expected to expire, allowing for broader biosimilar competition?
While specific patent expiry dates vary due to multiple patents and litigation, key patents providing foundational protection began to expire in the late 2010s and early 2020s. The effective market exclusivity has been extended by secondary patents and legal challenges.
What is the expected price reduction range for biosimilar eculizumab compared to Soliris upon initial launch?
Biosimilar eculizumab is generally expected to launch with a price discount ranging from 15% to 35% compared to the originator product, Soliris (NDC 68180-0894).
How will payers influence the adoption rate of biosimilar eculizumab?
Payers will significantly influence biosimilar adoption through formulary placement, co-payment structures, and the implementation of utilization management tools like prior authorization and step therapy, often favoring biosimil options to achieve cost savings.
Besides PNH and aHUS, are there any other indications where eculizumab is approved or being investigated?
Eculizumab is approved for PNH and aHUS. While research into other complement-mediated diseases may occur, significant expansion beyond these core indications has not yet materialized for this specific molecule.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products. Retrieved from [Relevant FDA Database/Search Tool] (Specific URL would depend on the search query and date). [2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [Relevant EMA Database/Search Tool] (Specific URL would depend on the search query and date). [3] Pharmaceutical company press releases and investor reports (e.g., AstraZeneca/Alexion, Samsung Bioepis, Amgen). (Dates of reports would be cited). [4] Market research reports on biosimilar and orphan drug markets. (Specific report titles and publishers would be cited). [5] Legal databases reporting on patent litigation cases related to eculizumab. (Specific case names and court documents would be cited).
More… ↓
